clinical trial · NCT07009860
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
Alcohol Liver DiseasePemvidutidePlacebo
brief summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
started
Jun 16, 2025
primary completion
Mar 31, 2027
completion
Aug 31, 2027
last updated
Mar 20, 2026
official title
RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol